Sentences with phrase «hip bone mineral density»

Total hip bone mineral density was maintained in the HRT alone group (+0.4 + / - 0.4 %) and increased in the HRT + T group (+ 1.8 + / - 0.5 %).85 (That said, it would be much safer to use a topical delivery form for these hormones; there are serious problems with taking either estrogen or testosterone orally.

Hip bone mineral densities also increased in the first six months after stopping PrEP and returned to normal levels by a median follow - up time of 73 weeks.

Not exact matches

The six women, who had received continuous denosumab for seven years, had substantial gains in bone mineral density (BMD)-- increasing 18.5 % in the spine and 6.9 % in total hip.

The small increase in the high - dose group did not translate into beneficial effects because authors found no difference between the three study groups for changes in spine, average total - hip, average femoral neck or total - body bone mineral density, trabecular bone score, muscle mass or sit - to - stand tests.

To measure whether MHT influenced bone health, researchers used dual x-ray absorptiometry (DXA) scans of the participants» lumbar spine, femoral neck and hip to assess bone mineral density.

A new study published today in The Lancet reveals that a simple questionnaire, combined with bone mineral density measurements for some, would help identify those at risk of hip fracture.

The authors measured hip and spine bone mineral density (BMD) at 12 and 24 months, as well as adverse events, which included falls.

For all three groups, researchers measured bone mineral content and density in the spine, neck, hip and the whole body, and looked at current height and weight, smoking, level of physical activity and a variety of other measures.

The DXA scans evaluated bone mineral density, a surrogate measurement of bone strength, as well as bone mineral content, which is the weight of bone, at both the hip and the lumbar spine (lower back).

In both studies, patients receiving TAF experienced a significantly smaller mean percentage decrease from baseline in hip and spine bone mineral density at week 48 (p < 0.001), and had smaller changes in renal tubular markers (p < 0.001) than TDF.

The key safety endpoints were changes in hip and spine bone mineral density (a measure of minerals mainly calcium in bones), changes in serum creatinine (a waste product in blood that is removed by healthy kidneys) and dipstick proteinuria (protein excreted in urine).

One variant was also associated with bone mineral density in the thigh bone at the hip (the «neck» of the femur).

Potential cardioprotection was based on generally supportive data on lipid levels in intermediate outcome clinical trials, trials in nonhuman primates, and a large body of observational studies suggesting a 40 % to 50 % reduction in risk among users of either estrogen alone or, less frequently, combined estrogen and progestin.2 - 5 Hip fracture was designated as a secondary outcome, supported by observational data as well as clinical trials showing benefit for bone mineral density.6, 7 Invasive breast cancer was designated as a primary adverse outcome based on observational data.3, 8 Additional clinical outcomes chosen as secondary outcomes that may plausibly be affected by hormone therapy include other cardiovascular diseases; endometrial, colorectal, and other cancers; and other fractures.3, 6,9

The research revealed that individuals increasing their intake of calcium and vitamin D generally increase bone mineral density along with reducing risk of hip fracture considerably.

The size, shape and mineral density of their hip and shin bones were also measured when they were 17 years old.

A study of post-menopausal women found that it increased bone mineral density in the hip area when the women stood with slightly bent knees.

Bone mineral density (BMD) of lumbar spine, forearm, hip, and whole body was assessed at baseline and at the end of the study using dual - energy X-ray absorptiometry.